CTXR vs OKTA · rev $7.1M vs P/E 84, rev $1.57B
Citius Pharmaceuticals Inc (CTXR) versus Okta Inc (OKTA) — a side-by-side from cached financials, not a winner call.
Citius Pharmaceuticals Inc (CTXR) is a biotechnology company listed on US.
Okta Inc (OKTA) is a software - infrastructure company listed on NASDAQ.
Latest reported CTXR revenue for 2026-06-30 was $7.1M. Net income was -$49.4M. Revenue was up 26.6% from 2026-03-31 to 2026-06-30. CTXR currently screens at market cap $13.4M.
Latest reported OKTA revenue for 2026-07-31 was $1.57B. Net income was $190.0M. OKTA currently screens at market cap $20.06B and trailing P/E 83.6.
CTXR currently screens at market cap $13.4M. OKTA currently screens at market cap $20.06B and trailing P/E 83.6.
Not investment advice. Open the CTXR and OKTA stock pages for the full models.
Not investment advice.